Viveca Biomed is pleased to announce the imminent relaunch of Contrelle Activgard across Europe, starting with the UK market. The business acquired the brand from Codan and has relocated manufacturing to a new purpose built medical device facility in the UK, which will be supplying global demand. The Viveca Biomed team brings years of pharmaceutical, medical device and consumer healthcare experience to the new business, focusing solely on female healthcare.
“The business is totally focused on bringing Contrelle Activgard back to market as soon as possible,” said Jacqui Peacock, Viveca Biomed’s Commercial Director. “We apologise for the disruption of supplies to customers in the transition period, and wish to assure existing and new customers our new production facility provides the opportunity of significantly increasing volume.” Jacqui adds, “We are pleased at the level of support we have received and understanding of how Contrelle Activgard fits into women’s lives”.
Contrelle Activgard is indicated for stress incontinence and is a simple concept that treats the problem rather than the symptoms, working actively rather than passively. It gives a gentle support that lifts the bladder at the same time as adapting perfectly to the movements of the body. Clinical data reinforces the major benefits Contrelle offers to patients with objective evaluations showing over a third of patients became totally continent and 77% reporting an improvement.
The team are looking forward to working with clinicians across Europe to continue to develop Contrelle and other new technologies the company is developing, and invite healthcare professionals to contact them as soon as possible to reserve new supplies.
Please contact Viveca Biomed by email, or call for immediate help.
T: +44 (0)797 494 9766 / +44 (0)1590 644403